Panobinostat

BNF:
Not listed
Status:
Red
Decision Date:
January 2016
 

Comments

RED1,2,3,4: NICE TA370: Panobinosat in combination with Bortezomib and dexamethasone for treating multiple myeloma after at least 2 previous treatments.

NHS England drug. To be used in line with NHS England commissioning intentions

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 4: Specifically designated as “hospital only” by product licence or by DH/NICE

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app